7335 related articles for article (PubMed ID: 1420599)
1. Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor.
Lagoo-Deenadayalan S; Lagoo AS; Hardy KJ; Grimm EA
Lymphokine Cytokine Res; 1992 Aug; 11(4):207-13. PubMed ID: 1420599
[TBL] [Abstract][Full Text] [Related]
2. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
Munn DH; Cheung NK
Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
[TBL] [Abstract][Full Text] [Related]
4. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
5. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
6. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
7. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
[TBL] [Abstract][Full Text] [Related]
9. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
10. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction.
Fujiwara T; Grimm EA
J Immunol; 1992 May; 148(9):2941-6. PubMed ID: 1374105
[TBL] [Abstract][Full Text] [Related]
11. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
13. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
14. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2.
Morgan AC; Sullivan W; Graves S; Woodhouse CS
Cancer Res; 1989 May; 49(10):2773-6. PubMed ID: 2785437
[TBL] [Abstract][Full Text] [Related]
15. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect of IL-2 and IL-6 on the lytic activity of purified human peripheral blood large granular lymphocytes.
Smyth MJ; Ortaldo JR
J Immunol; 1991 Feb; 146(4):1380-4. PubMed ID: 1991975
[TBL] [Abstract][Full Text] [Related]
17. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
18. Characterization and utilization of a monoclonal antibody inhibiting porcine natural killer cell activity for isolation of natural killer and killer cells.
Dato ME; Kim YB
J Immunol; 1990 Jun; 144(11):4452-62. PubMed ID: 1971298
[TBL] [Abstract][Full Text] [Related]
19. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
